S&P 500

5.315,59

0,16%

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
NeuroSense Therapeutics Ltd (NRSN)
NeuroSense Therapeutics Ltd (NRSN) Notícias

NRSN

NeuroSense Therapeutics (NRSN)

NeuroSense Therapeutics Ltd

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:NRSN

1 2 3 4 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
20/05/2024	10:00	PR Newswire (US)	NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
14/05/2024	10:05	PR Newswire (US)	NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
07/05/2024	09:45	PR Newswire (US)	NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
02/05/2024	10:19	PR Newswire (US)	NeuroSense Announces First Quarter 2024 Business Update	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
22/04/2024	09:30	PR Newswire (US)	NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
18/04/2024	09:30	PR Newswire (US)	NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
12/04/2024	09:30	PR Newswire (US)	NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
10/04/2024	20:16	PR Newswire (US)	NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
09/04/2024	09:30	PR Newswire (US)	NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
05/04/2024	10:29	PR Newswire (US)	NeuroSense Announces Year End 2023 Financial Results and Provides Business Update	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
22/02/2024	10:25	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
21/02/2024	10:30	PR Newswire (US)	NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
13/02/2024	15:20	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
07/02/2024	11:27	PR Newswire (US)	NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
09/01/2024	10:45	PR Newswire (US)	NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
27/12/2023	19:03	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
27/12/2023	19:00	PR Newswire (US)	NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
14/12/2023	11:24	PR Newswire (US)	NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
05/12/2023	10:00	PR Newswire (US)	NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
05/12/2023	02:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
04/12/2023	18:01	PR Newswire (US)	NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
04/12/2023	08:17	Edgar (US Regulatory)	Form POS AM - Post-Effective amendments for registration statement	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
28/11/2023	10:45	PR Newswire (US)	NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
13/11/2023	11:20	PR Newswire (US)	NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
09/11/2023	11:00	PR Newswire (US)	NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
06/11/2023	10:30	PR Newswire (US)	NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
01/11/2023	10:00	PR Newswire (US)	NeuroSense Therapeutics to Participate in BIO-Europe Fall	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
17/10/2023	09:30	PR Newswire (US)	NeuroSense CEO Provides Q3 2023 Update	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
04/10/2023	10:10	PR Newswire (US)	NeuroSense's PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Model	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
20/09/2023	10:05	PR Newswire (US)	European Medicines Agency Grants NeuroSense SME Status	NASDAQ:NRSN	NeuroSense Therapeutics Ltd